Skip to content
On this page:OverviewPublicationsResearchersInstitutionsOpen access
PICO Portalanswers from OpenAlex

CRISPR Therapeutics (Switzerland)

InstitutionResearch output, impact & collaborations

CRISPR Therapeutics (Switzerland) is a institution indexed in PICO Portal from OpenAlex.

What is known about CRISPR Therapeutics (Switzerland)?

PICO Portalrecord summary

CRISPR Therapeutics (Switzerland) is a research organisation in Basel, CH. OpenAlex records 120 works and 10,687 citations for it. 94 researchers list it as their most recent affiliation.

How many works does CRISPR Therapeutics (Switzerland) have?

PICO Portalindexed works

CRISPR Therapeutics (Switzerland) has 120 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does CRISPR Therapeutics (Switzerland) have?

PICO Portalcitation count

CRISPR Therapeutics (Switzerland) has 10,687 citations in the OpenAlex counts PICO Portal stores.

How many researchers are at CRISPR Therapeutics (Switzerland)?

PICO Portalresearcher count

CRISPR Therapeutics (Switzerland) has 94 researchers in the PICO Portal index.

What is the average h-index at CRISPR Therapeutics (Switzerland)?

PICO Portalavg h-index

CRISPR Therapeutics (Switzerland) has an average h-index of 5 in OpenAlex.

What is the ROR of CRISPR Therapeutics (Switzerland)?

PICO Portalror

The ROR for CRISPR Therapeutics (Switzerland) is on the source record.

What is the OpenAlex record for CRISPR Therapeutics (Switzerland)?

PICO Portalopenalex

The OpenAlex for CRISPR Therapeutics (Switzerland) is on the source record.

Who are the most-cited researchers behind CRISPR Therapeutics (Switzerland)?

PICO Portaltop researchers by citations
1
Ainsley Ross · Glioma Diagnosis and Treatment
12 works365 citations

What are the most-cited papers on CRISPR Therapeutics (Switzerland)?

PICO Portalmost cited works
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
Andrew D. Norden, Jan Drappatz, Alona Muzikansky, Karly David, Mary Gerard, M. Brenna McNamara, Phuong Phan, Ainsley Ross, Santosh Kesari, Patrick Y. Wen
Journal of Neuro-Oncology. 2008139 Citations
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson
Joshua J. Field, Gene Lin, Maureen Okam, Elaine M. Majerus, Jeffrey R. Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan
Blood. 2013100 CitationsOPEN ACCESS
Comparative rates of adverse events with different formulations of intravenous iron
Maureen Okam, Elyse Mandell, Nathanael D. Hevelone, Wentz Rachel, Ainsley Ross, Gregory A. Abel
American Journal of Hematology. 201258 CitationsOPEN ACCESS
CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul Shaughnessy, Armin Ghobadi, Michael Bishop, Ana Alfonso Piérola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William B. Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant-Cohen, Richard T. Maziarz, Carlos Bachier
Blood. 202257 Citations
Sickle cell disease (SCD), iNKT cells, and regadenoson infusion.
David G. Nathan, Joshua J. Field, Gene Lin, Donna Neuberg, Elaine M. Majerus, Onyinye Onyekwere, Jeffrey R. Keefer, Maureen Okam, Ainsley Ross, Joel Linden
PubMed. 20128 CitationsOPEN ACCESS

How much of the research on CRISPR Therapeutics (Switzerland) is open access?

PICO Portalopen access share
30%OPEN ACCESS
Gold
0%
Green
10%
Hybrid
0%
Bronze
20%
Closed
70%

Related on PICO Portal

470M+ articles · 14-day free trial